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Abstract
Introduction: Osteoarthritis (OA) is a degenerative joint disease affecting a large population of people. The
mechanism of this highly prevalent disease is not fully understood. Currently there is no effective disease-modifying
treatment for OA. The purpose of this study was two-fold: 1) to investigate the role of MMP13 in the development of
OA; and 2) to evaluate the efficacy of the MMP13 inhibitor CL82198 as a pharmacologic treatment for preventing OA
progression.
Methods: To investigate the role of the endogenous Mmp13 gene in OA development, tamoxifen was administered to
two-week-old Col2CreER;Mmp13fx/fx (Mmp13Col2ER) and Cre-negative control mice for five days. OA was induced by
meniscal-ligamentous injury (MLI) when the mice were 10 weeks old and MLI or sham-operated joints were harvested
4, 8, 12, or 16 weeks after surgery. To evaluate the efficacy of CL82198, MLI surgery was performed on 10-week-old wild
type mice. CL82198 or saline was administered to the mice daily beginning immediately after the surgery for up to
16 weeks. The joint tissues collected from both experiments were evaluated by cartilage grading, histology/
histomorphometry, immunohistochemistry (IHC), and terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining. The ability of CL82198 to inhibit MMP13 activity in vitro was confirmed by ELISA.
Results: The OA progression was decelerated in Mmp13Col2ER mice 8, 12, and 16 weeks post-surgery. Cartilage grading
by blinded observers confirmed decreased articular cartilage degeneration in Mmp13Col2ER mice at 8, 12 and 16 weeks
compared to Cre-negative mice. Histomorphometric analysis demonstrated that Mmp13Col2ER mice had a higher
articular cartilage area and thickness at 12 and 16 weeks post-surgery compared to the control mice. Results of IHC
revealed greater type II collagen and proteoglycan expression in Mmp13Col2ER mice. Chondrocyte apoptosis, as
determined by TUNEL staining, was higher in control mice compared to Mmp13Col2ER mice. CL82198 inhibited MMP13
activity in conditioned media from vehicle (> 85%) or bone morphogenetic protein 2 (BMP2)-treated (> 90%) primary
murine sternal chondrocytes. Intraperitoneal injection of CL82198 decelerated MLI-induced OA progression, increased
type II collagen and proteoglycan levels, and inhibited chondrocyte apoptosis compared to saline treatment as
determined by OA grading, histology, histomorphometry, IHC, and TUNEL staining, respectively.
Conclusions: Mmp13 is critical for OA progression and pharmacologic inhibition of MMP13 is an effective strategy
to decelerate articular cartilage loss in a murine model of injury-induced knee OA.
Introduction
Osteoarthritis (OA) is a degenerative joint disease and is a
major cause of disability. Currently, there is no treatment
capable of altering its progression. The major pathological
characteristics of OA include progressive loss of articular
cartilage, osteophyte formation, and changes in peri-
articular and subchondral bone [1,2]. The articular
cartilage receives most of the attention in OA studies
because the primary pathologic feature seen in OA is
gross articular cartilage damage.
Matrix metalloproteinase (MMP) 13 is a major enzyme
that targets cartilage for degradation. Compared to other
MMPs, the expression of MMP13 is more restricted to
connective tissue [3]. It not only targets type II collagen in
cartilage for degradation, but also degrades proteoglycan,
types IV and type IX collagen, osteonectin and perlecan in
cartilage [4]. Clinical investigation revealed that patients
with articular cartilage destruction have high MMP13
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expression [5], suggesting that increased MMP13 may be
associated with cartilage degradation. Studies have also
shown that Mmp13-overexpressing transgenic mice
develop a spontaneous OA-like articular cartilage destruc-
tion phenotype [6]. The ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motifs) family of
aggrecanases also contributes to proteoglycan/aggrecan
depletion and are associated with cartilage degradation
during OA. ADAMTS4 and 5 were identified as the major
aggrecanases during OA development. Deletion of the
Adamts5 gene or double knockout of Adamts4 and
Adamts5 prevented cartilage degradation in a surgically
induced murine knee OA model [7,8]. These findings indi-
cate that catabolic enzymes play a significant role in OA
progression and support the development of therapies tar-
geting these enzymes as a strategy to decelerate articular
cartilage degradation.
Meniscal injuries are among the most common causes
of post-traumatic OA in humans. The meniscus is a
C-shaped cartilage that functions as a shock-absorbing,
load bearing, stability enhancing, and lubricating cush-
ion in the knee joint. Studies show that loss of meniscus
integrity and function leads to OA in humans [9,10].
The meniscal-ligamentous injury (MLI)-induced murine
OA model was initially developed by Clements et al.
[11] and this injury model has been further modified
and developed in recent studies [12]. This mouse model
also permits study of the development of trauma-
induced OA in defined genetic backgrounds. In this
model, the ligation of the medial collateral ligament
coupled with disruption of the meniscus from its ante-
rior-medial attachment induces reproducible OA devel-
opment over a three-month period [12]. In the present
studies, we will determine the role of MMP13 in MLI-
induced OA progression. We will use Col2CreER;
Mmp13fx/fx (Mmp13Col2ER) mice to block Mmp13
expression in chondrocytes and use MMP13 inhibitors
to inhibit MMP13 activity.
Methods
Meniscal/ligamentous injury-induced osteoarthritis model
and treatment of MMP13 inhibitor
Wild type C57BL/6J and Mmp13fx/fx mice [13] were
obtained from Jackson Laboratories (Bar Harbor, ME,
USA). Col2CreER transgenic mice [14] were crossed with
Mmp13fx/fx mice to generate Col2CreER;Mmp13fx/fx mice
(referred to hereafter as Mmp13Col2ER mice) (Table 1).
Tamoxifen (Sigma, St. Louis, MO, USA) was administered
to two-week-old Mmp13Col2ER mice and littermate con-
trols by intraperitoneal (i.p.) injection (1 mg/10 g body
weight) for five days. MLI surgery was performed
to induce knee OA [12] in 10-week-old Mmp13Col2ER
and Cre-negative control mice. Details regarding MLI sur-
gery were previously described [12]. The surgery was
performed on the right hind limbs as follows: 1) following
anesthesia, making a 5 mm parapatellar; 2) identifying and
transecting the medial collateral ligament with a 25 gauge
needle; 3) applying valgus stress to the knee to confirm
disruption and provide access to the meniscus; 4) detach-
ing and partially removing the anterior horn of the medial
meniscus; 5) closing of the wound with 4.0 nylon sutures
applied in an interrupted pattern. The left hind limb was
used as a control. The left hind limb was opened and the
structures of the knee were exposed and then the skin
incision closed without manipulating the joint tissue. Pre-
and post-surgery, mice were provided analgesia (2.5 mg/kg
banamine, i.p. injection) every 24 hours for 72 hours and
the sutures were removed after 10 days. Both left and right
knee joints were harvested, processed, sectioned and
stained 4, 8, 12, and 16 weeks post-surgery (n = 5 in each
group). MLI and sham surgeries were also performed on
10-week-old C57BL/6J mice (n = 5 in each group). The
MMP13 inhibitor CL82198 (Tocris Bioscience, Minneapo-
lis, MN, USA) was administered to wild type mice begin-
ning one day after surgery by i.p. injection every other day
for up to 16 weeks at doses of 1, 5, 10 mg/kg body weight.
Normal saline was used as a control. Knee joints were col-
lected, sectioned and stained 12 weeks post-surgery (n = 5
in each group). All protocols were approved by the Institu-
tional Animal Care and Use Committee (IACUC) at the
University of Rochester.
Histology and histomorphometry
Knee joints from each group were harvested and prepared
for sectioning and analysis. Samples were fixed in 10%
neutral buffered formalin (VWR, Radnor, PA, USA) for
three days, then decalcified with formic acid (Decal Che-
mical Corp., Suffern, NY, USA) for seven days. After neu-
tralizing with Cal-arrest (Decal Chemical Corp.), samples
were processed and embedded in paraffin. Three μm thick
mid-saggital sections at three different levels (50 μm apart)
were cut from the medial compartment of the joints. The
sections were stained with Alcian blue/H&E (AB/H&E)
and safranin O/Fast Green (SO/FG). Histomorphometric
measurements were performed using OsteoMeasure soft-
ware (OsteoMetrics, Inc., Atlanta, GA, USA). AB/H&E- or
SO/FG-stained areas were outlined on projected images of
each histologic section to determine articular cartilage
area and thickness.
Table 1 Breeding of Col2CreER;Mmp13fx/fx mice
(Mmp13Col2ER).
Breeding Desired progeny
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Immunohistochemistry and TUNEL staining
Three μm thick paraffin sections were baked at 60°C over-
night. Slides were then deparaffinized, rehydrated, and
digested with pepsin. DAKO endogenous blocking reagent
(Dako S2003, Carpinteria, CA, USA) was then used to
quench endogenous peroxidase for 10 minutes. Normal
horse serum or normal goat serum (Vector S-2000, Burlin-
game, CA, USA) was used to block non-specific binding
sites for 20 minutes. Collagen II or collagen X primary
antibodies (Thermo Scientific, Rockford, IL, USA) were
added and the slides were incubated at 4°C overnight.
Secondary biotinylated horse anti-mouse antibody (Vector
BA-2000) or goat anti-mouse antibody (Vector BA-9200)
was added for 30 minutes on the second day, followed by
incubation with streptavidin (Pierce 21130, Rockford, IL,
USA) for 30 minutes. Positive staining was detected by
Romulin AEC Chromagen (Biocare Medical RAEC810L,
Concord, CA, USA). To detect chondrocyte apoptosis
after meniscal surgery, terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) staining was
performed using a kit based on the manufacturer’s instruc-
tion (Promega, Fitchburg, WI, USA).
Grading of cartilage structure
Tissue sections were stained with Alcian blue/Orange G
and graded by two blinded observers based on the scoring
system developed by Chambers et al. [7]. In brief, each
section was assigned a grade as follows: 0 = normal carti-
lage, that is, lack of superficial zone fibrillation or clefting;
1 = mild superficial fibrillation; 2 = fibrillation and/or
clefting extending below the superficial zone; 3 = mild
(< 20%) loss of articular cartilage; 4 = moderate (20% to
80%) loss of articular cartilage; 5 = focal loss of cartilage to
the subchondral bone (eburnation); 6 = severe (> 80%)
loss of articular cartilage. The progression of OA in differ-
ent groups was evaluated using this method. Three slides
of each sample were analyzed and five mice were used in
each group.
MMP13 activity assay
The ability of CL82198 to inhibit MMP13 activity in vitro
was determined using the SensoLyte 520 MMP13 Assay
Kit (AnaSpec, Fremont, CA, USA). Five ng of MMP13 and
10 μg/mL of CL82198, or control substrate were added
into the MMP13 Assay Kit. MMP13 activity was detected
following the manufacturer’s instructions. Primary sternal
chondrocytes were isolated from three-day-old wild-type
(WT) pups as previously described [15]. Cells were plated
in 12-well-plates and treated with bone morphogenetic
protein 2 (BMP-2) (100 ng/ml) alone or BMP-2 with the
MMP-13 inhibitor CL82198 (1, 5 and 10 μM) for 60
hours. The culture media were collected and MMP13
activity was determined using the SensoLyte 520 MMP13
Assay Kit (AnaSpec) following the manufacturer’s
instructions.
Statistical analysis
Results of all quantitative assays involving multiple doses
and time points were analyzed using analysis of variance
(ANOVA) followed by Dunnett’s test. For experiments
comparing two groups, unpaired student’s t-test was
applied. P < 0.05 was considered to be a significant
difference.
Results
OA progression was decelerated in Mmp13Col2ER mice
To investigate if Mmp13 deletion could prevent or decele-
rate MLI-induced OA, we crossed Col2CreER transgenic
mice [14,16] with Mmp13fx/fx mice [13] to generate
Col2CreER;Mmp13fx/fx mice (Mmp13Col2ER) (Table 1).
Deletion of the Mmp13 gene in chondrocytes had no sig-
nificant effect on articular and growth plate chondrocyte
morphology [see Additional file 1]. Tamoxifen was admi-
nistered (i.p., five days) to two-week-old Mmp13Col2ER
mice and had no effect on articular and growth plate carti-
lage [see Additional file 1]. MLI surgery was performed
when the mice were 10-weeks-old to induce OA. Knee
joints were harvested 4, 8, 12, and 16 weeks post-surgery
(n = 5 in each group). Histology showed that four weeks
post-MLI surgery, articular cartilage was nearly normal in
both Mmp13Col2ER and Cre-negative control groups
(Figure 1A). OA-like fibrillation, clefting and cartilage loss
down to the tidemark appeared 8 weeks post-surgery
and worsened at the 12- and 16-week time points in Cre-
negative control mice. In Mmp13Col2ER mice, however,
there was markedly less articular cartilage excavation,
especially at the 12- and 16-week time points (Figure 1A).
OA grading likewise revealed significantly reduced carti-
lage degeneration at 8, 12 and 16 weeks post-surgery in
Mmp13Col2ER mice compared to the control group (Figure
1B). To quantify OA progression, we performed histomor-
phometry using the OsteoMeasure system. The results
showed that articular cartilage area and articular cartilage
thickness at proximal tibiae, total cartilage area, and total
cartilage thickness progressively decreased at 8, 12, and
16 weeks post-surgery (Figure 1C-F), but this progression
was decelerated in Mmp13Col2ER mice compared to the
control group. Articular cartilage area and articular carti-
lage thickness at proximal tibiae were significantly greater
at 12 and 16 weeks post-surgery in Mmp13Col2ER groups
(Figure 1C-D). Total cartilage area was significantly differ-
ent at 16 weeks post-surgery (Figure 1E), and total carti-
lage thickness was significantly different at 8, 12, and
16 weeks post-surgery (Figure 1F). Articular cartilage area
and thickness at distal femora had no significant changes
at any time point post-surgery.
Wang et al. Arthritis Research & Therapy 2013, 15:R5
http://arthritis-research.com/content/15/1/R5
Page 3 of 11
Figure 1 Decelerated osteoarthritis progression in Mmp13Col2ER mice. Tamoxifen was administered when matrix metalloproteinase (MMP13)
conditional knockout (cKO) mice (Mmp13Col2ER) and Cre-negative control mice were two weeks old (1 mg/10 g body weight, i.p., daily for five
days). Meniscal-ligamentous injury (MLI)-induced osteoarthritis (OA) surgery was performed on the right hind-limbs when the mice were 10 weeks
old. The left hind-limbs were used as sham controls. (A) Knee joint samples were harvested 4, 8, 12, or 16 weeks post-surgery and Alcian blue/
Hematoxylin/Orange G staining was performed. Histological results showed decreased articular cartilage degradation in Mmp13Col2ER mice 8, 12 and
16 weeks post-surgery. (B) Histological grading by blinded observers confirmed decreased articular cartilage degradation in Mmp13Col2ER mice at 8,
12, and 16 weeks compared to control Cre-negative mice (*P < 0.05). (C) Tibia articular cartilage area was quantified by tracing the Alcian blue-
positive area in the proximal tibia. There was no significant difference 4 and 8 weeks post-surgery in Mmp13Col2ER MLI mice versus control MLI mice.
The tibia cartilage area was increased 21% in Mmp13Col2ER MLI mice compared to control MLI mice 12 weeks post-surgery (*P < 0.05) and increased
31% 16 weeks post-surgery (*P < 0.05). (D) Tibia thickness was quantified by tracing the Alcian blue-positive thickness in the center of the tibial
plateau. There was no significant difference in tibial cartilage thickness at 4 or 8 weeks post-surgery. Tibia cartilage thickness was increased 29% in
Mmp13Col2ER MLI mice compared to control MLI mice 12 weeks post-surgery (*P < 0.05) and increased 50% 16 weeks post-surgery (*P < 0.01).
(E) Total articular cartilage area was quantified by tracing the Alcian blue-positive area in both the proximal tibia and distal femur. No significant
differences were detected 4, 8, and 12 weeks post-surgery. Total cartilage area increased 18% in Mmp13Col2ER MLI mice compared to control MLI
mice 16 weeks post-surgery (*P < 0.01). (F) Total cartilage thickness was quantified by tracing the Alcian blue-positive thickness in the center of the
proximal tibia and distal femur. No significant differences were detected at 4, 8, and 12 weeks post-surgery. Total cartilage thickness increased 39%
in Mmp13Col2ER MLI mice compared to control MLI mice 16 weeks post-surgery (*P < 0.01).
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Col2 and proteoglycan loss and chondrocyte apoptosis are
reduced in Mmp13Col2ER mice
Safranin O/Fast green (SO/FG) staining and IHC of
Col2 and ColX were performed on both Mmp13Col2ER
and control mice eight weeks post-surgery. The results
showed greater proteoglycan and Col2 content in the
Mmp13Col2ER mice (Figure 2A-B). The results of IHC
revealed increased ColX in both the Mmp13Col2ER and
Cre-negative control groups following MLI, but the
injury-associated induction was reduced in the
Mmp13Col2ER mice (Figure 2C). To investigate chondro-
cytes apoptosis, we performed TUNEL staining on knee
joints eight weeks post-surgery in Mmp13Col2ER and
control mice. Results of TUNEL staining revealed that
28% of chondrocytes in articular cartilage underwent
apoptosis in control mice that received MLI while only
Figure 2 Decelerated osteoarthritis progression in Mmp-13Col2ER mice. Tamoxifen was administered when matrix metalloproteinase (MMP13)
conditional knockout (cKO) mice (Mmp13Col2ER) and Cre-negative control mice were two-weeks-old (1 mg/10 g body weight, intraperitoneal
injection, daily for five days). Meniscal-ligamentous injury (MLI) surgery was performed when the mice were 10-weeks-old. Knee joints were
harvested eight weeks post-surgery. (A) Safranin O/Fast Green staining was performed to evaluate proteoglycan content. Proteoglycan loss
following MLI was reduced in Mmp13Col2ER mice. (B) Type II collagen (Col2) loss following MLI was reduced in Mmp13Col2ER mice.
Immunohistochemistry (IHC) of Col2 was performed to assess its protein level. (C) IHC of ColX was performed to assess its protein level. Type X
collagen (ColX) induction following MLI was reduced in Mmp13Col2ER mice. (D) Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining (in green) and 4’,6-diamidino-2-phenylindole (DAPI) nuclear counterstaining (in blue) were performed to assess chondrocyte
apoptosis. Chondrocyte apoptosis following MLI was reduced in Mmp13Col2ER mice. (E) Quantification of TUNEL staining positive cells was
performed to assess chondrocyte apoptosis.
Wang et al. Arthritis Research & Therapy 2013, 15:R5
http://arthritis-research.com/content/15/1/R5
Page 5 of 11
6% of chondrocytes underwent apoptosis following MLI
in Mmp13Col2ER mice (Figure 2D and 2E).
CL82198 decelerates MLI-induced OA progression
We used CL82198, a selective MMP13 inhibitor, to
determine if inhibition of MMP13 activity can alter the
progression of OA-like degeneration in mice following
MLI surgery. Addition of 10 μg/ml of CL82198 together
with 5 ng active of MMP13 protein [17] blocked more
than 90% of MMP13 activity in vitro (Figure 3A). In
order to mimic the in vivo physiological situation more
closely, we isolated primary sternal chondrocytes from
three-day-old wild-type pups and treated the cells with
bone morphogenetic protein 2 (BMP2) alone, or BMP2
plus 1, 5, or 10 μM CL82198 for 60 hours. MMP13 activ-
ity in the conditioned media was determined using an
MMP13 assay kit. Results showed that after treatment
with BMP2, MMP13 activity in conditioned media was
significantly increased compared to vehicle control (Fig-
ure 3B). In contrast, treatment with 1 μM of CL82198
significantly inhibited MMP13 activity (84% inhibition).
More than 90% of MMP13 activity was inhibited by treat-
ment with 5 or 10 μM CL82198 (Figure 3B).
To investigate the efficacy of CL82198 in the inhibition
of OA progression, we performed MLI surgery on 10-
week-old WT mice, followed by i.p.injection of saline, 1, 5,
or 10 mg/kg of CL82198 [18] every other day, beginning
one day after surgery, for 12 weeks. Knee joints were har-
vested 12 weeks post-surgery. Histological results revealed
that OA progression, most notably cartilage loss down to
and even below the tidemark in saline control mice, was
decelerated with 1, 5, or 10 mg/kg of CL82198 injection,
particularly with the 10 mg/kg dose (Figure 3C). Cartilage
grading results were consistent and treatment with 5 and
10 mg/kg doses of CL82198 had significantly lower scores
than the saline control (Figure 3D). Histomorphometric
analysis revealed that the articular cartilage area at the
proximal tibiae was increased 9%, 15% and 43% (Figure
3E); total cartilage area was increased 21%, 19% and 38%
(Figure 3F); articular cartilage thickness at the proximal
tibiae was increased 11%, 37% and 70% (Figure 3G); and
total cartilage thickness was increased 23%, 27% and 50%
(Figure 3H) after injection of 1, 5, and 10 mg/kg of
CL82198, respectively.
CL82198 has protective effects on MLI-induced Col2 and
proteoglycan loss and chondrocyte apoptosis
SO/FG staining was performed to assess proteoglycan
content, and IHC was performed to evaluate Col2 and
ColX protein levels in the mice with either saline or
CL82198 (10 mg/kg) treatment. Results revealed greater
proteoglycan and Col2 content in the CL82198 treatment
group following MLI surgery compared to the saline
treatment group (Figure 4A and 4B). Consistent with
these findings, ColX levels were significantly decreased
after CL82198 treatment compared to the saline control
group (Figure 4C). To assess chondrocyte apoptosis, we
performed TUNEL staining on samples from the saline
and 10 mg/kg CL82198 treatment groups. Results of
TUNEL staining demonstrated that 34% of chondrocytes
underwent apoptosis in saline control mice following
MLI, while only 15% of chondrocytes underwent apopto-
sis with CL82198 treatment (10 mg/kg) following MLI
(Figure 4D and 4E).
Discussion
OA is a degenerative joint disease and is the most preva-
lent form of arthritis. The major symptom of this disease
is progressive cartilage break down and eventual complete
loss of articular cartilage [1,19]. The pathogenesis of OA is
not well understood, and there is currently no treatment
to alter the progression of OA. In this study, we demon-
strated that cartilage-specific deletion of Mmp13 deceler-
ated the progression of OA. We also demonstrated that
the MMP13 inhibitor CL82198 prevents OA progression
in the MLI-induced murine knee OA model and may,
therefore, represent a novel treatment option for OA
patients to preserve articular cartilage and joint function
instead of simply alleviating OA symptoms as existing
treatments do.
Recently, Little et al. showed that global knockout of
Mmp13 could prevent articular cartilage erosion [20].
However, there are several limitations related to this study.
1) The Mmp13 global knockout mice have a few abnorm-
alities including focal regions of bony union in growth
plates, tendency of metaphyseal flaring and increased tra-
becular bone mass that may affect OA study [21]. 2) OA is
a chronic, progressive disease, and their study only
assessed articular cartilage degradation four- and eight-
weeks post-surgery-induced OA. 3) Their study relied on
semi-quantitative histologic methods to characterize OA
progression.
To understand better the role of MMP13 in OA devel-
opment and progression, we generated inducible cartilage-
specific Mmp13Col2ER mice. Tamoxifen was administered
when the mice were two-weeks-old, followed by MLI
knee joint surgery to induce OA in Mmp13Col2ER and Cre-
negative control mice [22,12]. Our results demonstrate
that while articular cartilage is nearly normal four weeks
post-surgery in both groups, injured mice progressively
develop an OA-like phenotype at the later 8-, 12-, and 16-
week time points. The histomorphometric data showed
that cartilage area and thickness at the proximal tibiae was
significantly different at 12 and 16 weeks post-surgery in
the Mmp13Col2ER group compared to the control group.
However, the total cartilage area and thickness only had a
significant difference at 16 weeks post-surgery. This
is likely because there was little evidence of cartilage
degeneration or loss on the femoral condyle in either
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Figure 3 CL82198 prevents and decelerates MLI-induced osteoarthritis progression. (A and B) CL82198 inhibits matrix metalloproteinase
(MMP13) activity in vitro. (A) Addition of 5 ng of MMP13, 5 ng of MMP13 and 10 μg/mL of CL82198, or substrate control into a 96-well plate.
MMP13 enzyme activity was determined using the SensoLyte 520 MMP13 Assay Kit, and showed that CL82198 could block > 90% MMP13
activity in vitro. (B) Primary sternal chondrocytes were isolated from three-day-old wild type pups. Cells were plated in 12-well plates and treated
with 100 ng bone morphogenetic protein 2 (BMP-2), 100 ng of BMP-2 and 1 μM of CL82198, 100 ng of BMP-2 and 5 μM of CL82198, 100 ng of
BMP-2 and 10 μM of CL82198, or vehicle control for 60 hours. Cell culture media was collected and MMP13 activity was determined and
showed that CL82198 could inhibit > 90% MMP13 activity produced by BMP-2-treated primary chondrocytes. (C) Inhibition of MMP13 by
CL82198 protects against meniscal-ligamentous injury (MLI)-induced osteoarthritis (OA). MLI and sham surgeries were performed on 10-week-old
wild type mice. CL82198 was administered to wild type mice one day after surgery by intraperitoneal injection every other day for 12 weeks at
doses of 1, 5, or 10 mg/kg body weight. Normal saline was used as a control. Knee joints were collected, and sectioned 12 weeks post-surgery,
and Alcian blue/Hematoxylin/Organge G staining was performed. (D) Histological grading by two blinded observers confirmed decreased
articular cartilage degradation in mice treated with 1, 5, and 10 mg/kg of CL82198 compared to saline control mice (*P < 0.001). (E) The articular
cartilage area at proximal tibiae was quantified by tracing the Alcian blue-positive area in the proximal tibia. Compared to saline MLI, tibial
cartilage area was increased 9, 15, and 43% after treatment with 1, 5, and 10 mg/kg of CL82198, respectively (*P < 0.05). (F) Total articular
cartilage area was quantified by tracing the Alcian blue-positive area in both the proximal tibia and the distal femur. Total cartilage area was
increased 21%, 19%, and 38% with treatment of 1, 5, and 10 mg/kg of CL82198, respectively (*P < 0.05). (G) Tibia cartilage thickness was
quantified by tracing the Alcian blue-positive thickness in the center of the tibial plateau. Compared to saline treatment, tibia cartilage thickness
was increased 11%, 37%, and 70% with treatment of 1, 5, and 10 mg/kg of CL82198, respectively (*P < 0.05). (H) Total thickness was quantified
by tracing the Alcian blue-positive thickness in both the proximal tibia and the distal femur. Total cartilage thickness was increased 23%, 27%,
and 50% after injection of 1, 5, or 10 mg/kg CL82198, respectively (*P < 0.05).
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experimental group at 4, 8, 12, or 16 weeks post-surgery,
which is consistent with previous studies using this model
[20,12].
In addition to morphologic changes in articular cartilage
structure, OA is also characterized by changes in matrix
composition as well as changes in articular chondrocyte
activity, including inappropriate levels of apoptosis
[23-25]. Col2 and proteoglycan content were decreased in
both Mmp13Col2ER and control groups following MLI sur-
gery. However, cartilage specific deletion of the Mmp13
gene partially prevented Col2 and proteoglycan loss. Dele-
tion of the Mmp13 gene inhibited MLI-induced ColX
expression as well. This finding is not unexpected as the
cartilage is more intact in Mmp13Col2ER mice compared to
control mice at each time point. TUNEL staining revealed
that articular chondrocytes underwent apoptosis in both
the control and Mmp13Col2ER group. However, deletion of
the Mmp13 gene dramatically reduced articular chondro-
cyte apoptosis following MLI, potentially because the
more intact cartilage in Mmp13Col2ER mice may provide
chondrocytes with environmental survival cues. Little et
al. also showed increased articular chondrocyte apoptosis
after surgery, but they did not identify a difference
between the control and the Mmp13 KO groups. In their
surgery model, they transected the medial meniscotibial
ligament to destabilize the medial meniscus. In our
Figure 4 CL82198 prevents and decelerates MLI-induced osteoarthritis progression. Meniscal-ligamentous injury (MLI) and sham surgeries
were performed on 10-week-old wild type mice. CL82198 was administered to wild type mice beginning one day after surgery by
intraperitoneal injection every other day for 12 weeks at doses of 10 mg/kg body weight. Normal saline was used as a vehicle control.
(A) Safranin O/Fast green staining was performed to assess proteoglycan content. Proteoglycan loss was reduced following CL82198 treatment.
(B) Immunohistochemistry (IHC) of type II collagen (Col2) was performed to assess its protein level. Col2 loss was reduced following CL82198
treatment. (C) IHC of ColX was performed to assess its protein level. Type X collagen (ColX) induction was reduced following CL82198 treatment.
(D) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (in green) and 4’,6-diamidino-2-phenylindole (DAPI) nuclear
counterstaining (in blue) were performed to assess chondrocyte apoptosis. Chondrocyte apoptosis was reduced following CL82198 treatment. (E)
Quantification of TUNEL staining positive cells was performed to assess chondrocyte apoptosis.
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surgery model, we transected the medial collateral liga-
ment, detached the anterior horn of the medial meniscus
from the tibial plateau, and created a tear. Thus, their sur-
gical procedure may elicit a milder OA phenotype than
our procedure, and this milder OA phenotype may be the
reason for the apparent disparity in the apoptosis results
in our and their studies.
Over the past 30 years, several MMP inhibitors have
been developed as candidates for the treatment of arthritis,
cancer and cardiovascular diseases [26]. However, most of
these compounds have failed for a variety of reasons,
including non-specificity and toxicity. Currently, no MMP
inhibitor has been used in clinics [27]. Recently, Baragi et
al. developed an MMP13 inhibitor, ALS 1-0635, and eval-
uated the efficacy of this compound in a rat OA model
[28]. They gave ALS 1-0635 to rats twice-daily beginning
one day before surgically-induced OA for three weeks, and
found that ALS 1-0635 has chondro-protective effects.
However, ALS 1-0635 only had an effect at a dose of 60
mg/kg. The large dose and frequent administrations of
this compound suggest a relatively low specificity for ALS
1-0635 compound.
To explore the therapeutic potential of MMP13 inhibi-
tion for OA treatment, we investigated the ability of
CL82198, a specific MMP13 inhibitor, to inhibit MMP13
activity in vitro. CL82198 is a chemical compound.
Unlike ALS 1-0635 and other MMP13 inhibitors which
exert their effects via metal chelation, CL82198 binds to
the S1’ pocket of MMP13 and showed no effects on
MMP-1, -9, or TACE [17]. We found that CL82198 can
block more than 90% of MMP13 activity when it reacts
with active MMP13 directly. Since cartilage degeneration
and articular chondrocyte dysfunction are hallmarks of
OA, we isolated primary sternal chondrocytes from
three-day-old WT pups to determine the effect of
CL82198 on the activity of MMP13 secreted by chondro-
cytes undergoing hypertrophy. We treated sternal chon-
drocytes with BMP2 (100 ng/ml) for 60 hours to induce
hypertrophy and MMP13 production/secretion. Mean-
while, the cells were also treated with CL82198 with
BMP2 to inhibit BMP2-induced MMP13 activity. We
found that CL82198 inhibited > 90% of MMP13 activity
produced by BMP2-treated primary chondrocytes.
Next, we determined the efficacy of CL82198 in vivo.
We performed MLI surgery on 10-week-old WT mice, fol-
lowed by i.p. injection of saline or 1, 5, or 10 mg/kg of
CL82198 [18] every other day, beginning one day after
surgery. Histological data revealed that OA progression
was decelerated following CL82198 administration, with
the most pronounced effect at 10 mg/kg. Results of carti-
lage grading and histomorphometric analysis were consis-
tent with histological data and treatment with CL82198 at
5 and 10 mg/kg doses resulted in significantly lower scores
than the saline control.
Consistent with histological and histomorphometric
findings, results from SO/FG staining and Col2 and ColX
IHC revealed less proteoglycan and Col2 loss and a
decreased ColX level in the CL82198 treatment group.
Results of TUNEL staining indicate that about 20% fewer
chondrocytes underwent apoptosis with treatment of
CL82198 (10 mg/kg) following MLI compared to saline
control mice. Taken together, these results suggest that
OA progression is decelerated by the application of a
MMP13 inhibitor.
Genetic manipulation is a powerful method to study the
genetic causes of diseases and chemical compound deliv-
ery in vivo is a practical approach to test the efficacy of
drug treatment. Here, we tested the role of MMP13 using
Mmp13 cKO mice and using a MMP13 inhibitor in a sur-
gically induced OA mouse model. Our studies suggest
that inhibition of MMP13 expression or activity could effi-
ciently prevent and decelerate OA progression. Our study
provides initial evidence showing that a MMP13 inhibitor
may have potential for the treatment of OA progression
although future investigation is still required.
Conclusions
Our study reveals that cartilage-specific deletion of the
Mmp13 gene or inhibition of MMP13 activity decelerates
the OA-like phenotype in a surgically induced OA
model. Our studies also indicate that MMP13 inhibition
could be used as a potential therapeutic strategy for pre-
vention and treatment of OA.
Additional material
Additional file 1: Deletion of the Mmp13 gene in chondrocytes at
the postnatal stage has no significant effect on articular and
growth plate cartilage morphology. Histological sections from 10-
week-old Cre-negative control and matrix metalloproteinase (MMP13)
conditional knockout (cKO) mice (Mmp13Col2ER) treated with or without
tamoxifen (tamoxifen was administered to two-week-old mice) were
stained with Alcian blue/Hematoxylin/Orange G. No significant changes
in articular and growth plate cartilage morphology were observed in
these mice.
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